Core Viewpoint - The report details a shareholding reduction by Shanghai Zhangjiang Biopharmaceutical Base Development Co., Ltd. in Shanghai Yinos Biotech Co., Ltd., decreasing its stake from 10.82% to 7.82% through a block trade of 4,229,388 shares at a price of 35.49 yuan per share, which does not affect the company's control or governance structure [6][15][20]. Group 1: Shareholding Changes - The information disclosure obligor held 15,250,141 shares before the transaction, representing 10.82% of the total shares, and after the transaction, it holds 11,020,753 shares, which is 7.82% of the total [5][6]. - The share reduction was executed through an inquiry transfer method, and the shares transferred cannot be sold by the buyer for six months [3][6]. - The transaction does not lead to a change in the company's controlling shareholder or actual controller [8][15]. Group 2: Transaction Details - The inquiry transfer price was set at 35.49 yuan per share, with the total number of shares transferred being 4,229,388 [15][20]. - The transfer was conducted without participation from the company's controlling shareholders, directors, supervisors, or senior management [15]. - The inquiry process involved 224 institutional investors, with 17 submitting valid bids, resulting in 15 investors receiving allocations [18][20]. Group 3: Compliance and Reporting - The information disclosure obligor confirmed that the report contains no false records, misleading statements, or significant omissions, and it assumes legal responsibility for the report's content [2][11]. - The report complies with relevant laws and regulations, ensuring a fair and transparent transfer process [20].
上海益诺思生物技术股份有限公司 简式权益变动报告书